Plan B Rx-to-OTC switch
This article was originally published in The Tan Sheet
Executive Summary
Nonprescription Drugs and Reproductive Health Drugs advisory committees will convene Dec. 16 to "consider the safety and efficacy of NDA 21-045, proposing OTC use of Plan B...for reducing the chance of pregnancy after unprotected sex if contraceptive failed, or birth control was not used." Meeting will begin at 8 A.M. at the Hilton, 620 Perry Parkway, Gaithersburg, Md. Women's Capital Corporation filed the switch application for the emergency contraceptive in April 2003. Barr Labs announced signing a letter of intent to purchase Plan B from WCC Oct. 2. Barr expects a definitive agreement to be reached by mid-November and says the acquisition will not affect efforts to switch the drug OTC (1"The Tan Sheet" Oct. 6, 2003, p. 3)...
You may also be interested in...
Barr Plans Move To OTC Market With Plan B Emergency Contraceptive
Barr Laboratories will continue to pursue an Rx-to-OTC switch for the emergency contraceptive Plan B following its planned acquisition of the product
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.